Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the results from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...

Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Small ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Compass Pathways surged Monday on growing enthusiasm for the company's psilocybin-based approach to treatment-resistant depression.

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

Investors might want to bet on COMPASS Pathways PLC Sponsored ADR (CMPS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass. If ...

Compass Pathways may be the first to benefit from an accelerated approval process.